Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
NICE has approved the first targeted treatment for chronic obstructive pulmonary disease (COPD), offering a new option to up ...
Nearly 30,000 people in England living with chronic obstructive pulmonary disease could see their lives transformed after the ...
A biologic injection that reduces chronic obstructive pulmonary disease (COPD) flare-ups by around a third has been approved for use on the NHS in England and Wales. The National Institute for Health ...
NICE has recommended dupilumab for adults with uncontrolled COPD and raised eosinophils, citing fewer exacerbations and ...
Pfizer Inc (PFE) announced an update on their ongoing clinical study.
The National Institute for Health and Care Excellence (NICE), has published final draft guidance recommending dupilumab as a ...
Nuance Pharma ("Nuance") today announced that the National Medical Products Administration (NMPA) of China has officially accepted for review the New Drug Application (NDA) for Ohtuvayre® ...
An innovative treatment that reduces exacerbations in some COPD patients by a third looks set to be approved for use by the NHS this year.
Temple Health is testing a tiny, flexible scaffold aimed at relieving a common problem for emphysema patients: overinflation ...
AJMC®: How is COPD definitively diagnosed in clinical practice, and how does this disease create a clinical burden on patients and caregivers? Dr Rali: COPD diagnosis requires both clinical context ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results